Trial Outcomes & Findings for Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement (NCT NCT03506347)

NCT ID: NCT03506347

Last Updated: 2020-01-27

Results Overview

Mean vancomycin concentration in fat measured in ug/g at surgical closure

Recruitment status

COMPLETED

Study phase

PHASE2/PHASE3

Target enrollment

24 participants

Primary outcome timeframe

Approximately 60 minutes post surgical incision

Results posted on

2020-01-27

Participant Flow

Participant milestones

Participant milestones
Measure
Vancomycin 15mg/kg IV
Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery. Vancomycin: Antibiotic
Vancomycin 500mg Intraosseous
Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the intraosseous regional administration (IORA) injection then deflated. Vancomycin: Antibiotic
Overall Study
STARTED
12
12
Overall Study
COMPLETED
12
12
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Vancomycin 15mg/kg IV
n=12 Participants
Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery. Vancomycin: Antibiotic
Vancomycin 500mg Intraosseous
n=12 Participants
Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated. Vancomycin: Antibiotic
Total
n=24 Participants
Total of all reporting groups
Age, Continuous
68 years
STANDARD_DEVIATION 8.29 • n=12 Participants
69.1 years
STANDARD_DEVIATION 8.15 • n=12 Participants
68 years
STANDARD_DEVIATION 8.07 • n=24 Participants
Sex: Female, Male
Female
7 Participants
n=12 Participants
5 Participants
n=12 Participants
12 Participants
n=24 Participants
Sex: Female, Male
Male
5 Participants
n=12 Participants
7 Participants
n=12 Participants
12 Participants
n=24 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
United States
12 participants
n=12 Participants
12 participants
n=12 Participants
24 participants
n=24 Participants

PRIMARY outcome

Timeframe: Approximately 60 minutes post surgical incision

Mean vancomycin concentration in fat measured in ug/g at surgical closure

Outcome measures

Outcome measures
Measure
Vancomycin 15mg/kg IV
n=72 fat
Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery. Vancomycin: Antibiotic
Vancomycin 500mg Intraosseous
n=72 fat
Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated. Vancomycin: Antibiotic
Vancomycin Concentration in Fat
6.0 ug/g
Standard Deviation 0.85
40.5 ug/g
Standard Deviation 8.08

PRIMARY outcome

Timeframe: Approximately 60 minutes post surgical incision

Mean vancomycin concentration in bone measured in ug/g at surgical closure

Outcome measures

Outcome measures
Measure
Vancomycin 15mg/kg IV
n=48 bone
Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery. Vancomycin: Antibiotic
Vancomycin 500mg Intraosseous
n=48 bone
Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated. Vancomycin: Antibiotic
Vancomycin Concentration in Bone
8.3 ug/g
Standard Deviation 0.77
26.9 ug/g
Standard Deviation 1.31

Adverse Events

Vancomycin 15mg/kg IV

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Vancomycin 500mg Intraosseous

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Mark Spangehl

Mayo Clinic

Phone: 480-342-2948

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place